Apogee Therapeutics Inc. (NASDAQ:APGE – Get Free Report) shares reached a new 52-week high on Tuesday . The company traded as high as $134.35 and last traded at $134.20, with a volume of 428060 shares traded. The stock had previously closed at $134.15.
Analyst Ratings Changes
A number of equities research analysts have recently issued reports on the company. Citigroup lowered Apogee Therapeutics from a “buy” rating to a “neutral” rating and upped their price target for the company from $125.00 to $135.00 in a research report on Tuesday, June 23rd. Wedbush cut shares of Apogee Therapeutics from an “outperform” rating to a “neutral” rating and set a $135.00 price objective for the company. in a research report on Monday, June 22nd. Guggenheim cut shares of Apogee Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday, June 23rd. Stifel Nicolaus reissued a “hold” rating and set a $135.00 target price (up from $133.00) on shares of Apogee Therapeutics in a research note on Wednesday, June 24th. Finally, UBS Group lowered shares of Apogee Therapeutics from a “buy” rating to a “neutral” rating and boosted their price objective for the company from $100.00 to $135.11 in a report on Tuesday, June 23rd. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fifteen have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $121.25.
View Our Latest Analysis on Apogee Therapeutics
Apogee Therapeutics Trading Down 0.1%
Apogee Therapeutics (NASDAQ:APGE – Get Free Report) last announced its quarterly earnings data on Monday, May 11th. The company reported ($1.06) EPS for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.01. On average, research analysts anticipate that Apogee Therapeutics Inc. will post -4.45 EPS for the current fiscal year.
Insider Buying and Selling at Apogee Therapeutics
In other Apogee Therapeutics news, CEO Michael Thomas Henderson sold 80,000 shares of the firm’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $132.54, for a total transaction of $10,603,200.00. Following the transaction, the chief executive officer directly owned 1,015,987 shares of the company’s stock, valued at approximately $134,658,916.98. This trade represents a 7.30% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Carl Dambkowski sold 26,400 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $132.60, for a total value of $3,500,640.00. Following the sale, the insider directly owned 179,248 shares of the company’s stock, valued at approximately $23,768,284.80. This represents a 12.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 182,900 shares of company stock valued at $21,711,585 in the last 90 days. 24.30% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Apogee Therapeutics
Several institutional investors and hedge funds have recently added to or reduced their stakes in APGE. GAMMA Investing LLC boosted its position in shares of Apogee Therapeutics by 40.5% during the 2nd quarter. GAMMA Investing LLC now owns 309 shares of the company’s stock worth $41,000 after purchasing an additional 89 shares in the last quarter. Rockefeller Capital Management L.P. purchased a new stake in Apogee Therapeutics during the fourth quarter worth about $25,000. Los Angeles Capital Management LLC acquired a new position in Apogee Therapeutics during the fourth quarter worth about $37,000. EverSource Wealth Advisors LLC increased its holdings in Apogee Therapeutics by 61.7% in the first quarter. EverSource Wealth Advisors LLC now owns 645 shares of the company’s stock valued at $54,000 after buying an additional 246 shares in the last quarter. Finally, Seven Fleet Capital Management LP acquired a new stake in shares of Apogee Therapeutics during the 4th quarter valued at approximately $136,000. Institutional investors and hedge funds own 79.04% of the company’s stock.
About Apogee Therapeutics
Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.
The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.
Featured Stories
- Five stocks we like better than Apogee Therapeutics
- Thematic Memory ETFs Give Investors a New Way to Play AI’s Hidden Bottleneck
- Rocket Lab Has Corrected Nearly 50%. Is It Still Too Expensive?
- Cybersecurity ETFs Are Rallying While AI Stocks Cool Off
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
Receive News & Ratings for Apogee Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apogee Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
